Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report - Takeaways - MDSpire

Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report

  • By

  • Antonella Mosca

  • Andrea Ficari

  • Maria Sole Basso

  • Carmen Mazzuca

  • Daniela Liccardo

  • Alessandro Fiocchi

  • Andrea Pietrobattista

  • Vincenzo Fierro

  • June 17, 2026

  • 0 min

Share

  • 1

    De novo post-transplant food allergy (dnPTFA) is common in pediatric liver transplant recipients, with prevalence significantly higher than in the general population.

  • 2

    Risk factors for dnPTFA include young age, female sex, atopy history, immunosuppressive therapy, and Epstein–Barr virus infection.

  • 3

    A 15-year-old boy developed severe asthma and multiple dnPTFAs after liver transplantation, despite low immunosuppression levels.

  • 4

    Omalizumab was initiated off-label at age 10, leading to excellent asthma control and a less restricted diet for the patient.

  • 5

    The patient's liver graft function remained stable over 5 years, supporting the long-term safety and effectiveness of omalizumab in this context.

Original Source(s)

Omalizumab for severe IgE-mediated food allergy and severe asthma after pediatric liver transplantation: a case report

  • by Antonella Mosca, Andrea Ficari, Maria Sole Basso, Carmen Mazzuca, Daniela Liccardo, Alessandro Fiocchi, Andrea Pietrobattista, Vincenzo Fierro

  • June 17, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Case Report: Atypical pediatric allergic bronchopulmonary aspergillosis masquerading as recurrent pneumonia

From anaphylaxis to eosinophilic esophagitis during omalizumab treatment in a boy with severe asthma and food allergy: a case report